ALBUMIN EXCRETION RATE AND METABOLIC MODIFICATIONS IN PATIENTS WITH ESSENTIAL-HYPERTENSION - EFFECTS OF 2 ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS

被引：20

作者：

PUIG, JG ^{[1
]}

MATEOS, FA ^{[1
]}

RAMOS, TH ^{[1
]}

LAVILLA, MP ^{[1
]}

CAPITAN, MC ^{[1
]}

GIL, A ^{[1
]}

机构：

[1] UNIV AUTONOMA MADRID,LA PAZ HOSP,DIV INTERNAL MED,MADRID,SPAIN

来源：

AMERICAN JOURNAL OF HYPERTENSION | 1994年 / 7卷 / 01期

关键词：

URINARY ALBUMIN EXCRETION; ESSENTIAL HYPERTENSION; ACE INHIBITORS; QUINAPRIL; CAPTOPRIL; CALCIUM;

D O I：

10.1093/ajh/7.1.46

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

A prospective randomized, double-blind, double-dummy study investigated the effects of two angiotensin converting enzyme (ACE) inhibitors on urinary albumin excretion in nondiabetic patients with mild to moderate essential hypertension. At the end of a 4-week placebo run-in period, 36 patients were randomly allocated to receive a 12-week course of treatment with quinapril (10, 20, or 40 mg) once daily or captopril (25, 50, or 75 mg) twice daily. Seventeen patients in each group completed the study. The mean change in mean blood pressure for patients taking quinapril (mean dose 32 mg/24 h) was -5 mm Hg (P =.002), and for patients taking captopril (mean dose 132 mg/24 h), -9 mm Hg (P =.002). The baseline urinary albumin excretion rate in both groups was (mean +/- EEM) 57 +/- 7 mu g/min. Fifteen patients in the quinapril group and 12 patients in the captopril group had baseline albumin excretion rates of more than 20 mu g/min. Mean urinary albumin excretion decreased in patients treated with quinapril from 55 to 33 mu g/min (mean decrease 22 mu g/min, 95% confidence interval [CI], 1 to 43 mu g/min; P =.031) and with captopril from 59 to 41 mu g/min (mean decrease 18 mu g/min, 95% CI, 3 to 32 mu g/min; P =.025). No significant modifications were observed in serum lipid concentrations, serum and urinary electrolytes, and magnesium or phosphorus metabolism. Mean urinary calcium excretion decreased in the quinapril-treated group (from 219 to 188 mg/24 h; P =.023) but not in the captopril group (from 264 to 267 mg/24 h). The mean variations in calcium excretion were significantly different between patients treated with quinapril (31 mg/24 h) and those receiving captopril (-3 mg/24 h; P .018). This study demonstrated that antihypertensive therapy with either quinapril or captopril significantly reduced urinary albumin excretion in nondiabetic patients with mild to moderate hypertension. The administration of quinapril elicited a calcium-sparing effect, the significance of which is unknown.

引用

页码：46 / 51

页数：6

共 14 条

[1]

The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V), Arch Intern Med, 153, pp. 154-183, (1993)

[2]

Kamper A.-L., Strandgaard S., Leyssac P.P., Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial, Am J Hypertens, 5, pp. 423-430, (1992)

[3]

Mogensen C.E., Petersen M.M., Hansen K.W., Christensen C.K., Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus, J Hypertens, 10, pp. S51-S53, (1992)

[4]

Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria, Br Med J, 302, pp. 210-216, (1991)

[5]

Ravid M., Savin H., Jutrin I., Et al., Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients, Ann Intern Med, 118, pp. 577-581, (1993)

[6]

De Venuto G., Reotti C., Matterei M., Pegoretti G., Long term captopril therapy at low doses reduces albumin excretion in patients with essential hypertension and no sign of renal impairment, J Hypertens, 3, pp. S143-S146, (1985)

[7]

Bianchi S., Bigazzi R., Baldari G., Campese V.M., Microalbuminuria in patients with essential hypertension: Effect of an angiotensin converting enzyme inhibitor and of a calcium channel blocker, Am J Hypertens, 4, pp. 291-296, (1991)

[8]

Valvo E., Casagrande P., Bedogna V., Et al., Systemic and renal effects of a new angiotensin converting enzyme inhibitor, benazepril, in essential hypertension, J Hypertens, 8, pp. 991-995, (1990)

[9]

McCarron D., Calcium metabolism and hypertension, Kidney Int, 35, pp. 717-736, (1989)

[10]

Laragh J.H., New angiotensin converting enzyme inhibitors. Their role in the management of hypertension, Am J Hypertens, 3, pp. 257S-265S, (1990)

← 1 2 →